secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2026-10-01T21:24:43+00:00
Accession:  0001437749-26-031767
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Pyxis Oncology raises $102.8M in offering; common warrants need shareholder approval to be exercisable
--------------------------------------------------------------------------------

- Sold 36,047,919 shares and 1,883,121 pre-funded warrants, each bundled with a common warrant for 1.3 shares, at a $2.90 combined price; offering closed October 1, 2026.
- Common warrants have a $3.50 strike and cannot be exercised until stockholders approve a charter amendment raising authorized shares, via a special meeting within 60 days of closing.
- Net proceeds were about $102.8 million; full cash exercise of all warrants would add roughly $162.2 million after a 6% solicitation fee to underwriters.
- Cash plus offering proceeds fund operations into the first half of 2028, but without warrant exercise the funds will not fully cover the planned Phase 3 Headliner trial in 2L+ R/M HNSCC.
- Proceeds go to advancing lead program MICVO; overall survival data from the Phase 1 monotherapy study is expected in the first half of 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000143774926031767/0001437749-26-031767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000143774926031767/pyxs20261001_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-031767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer